Skip to content

Study · Animal study (in vivo) · mouse · 2012

6 results

Hemodynamic actions and mechanisms of systemically administered α-MSH analogs in mice.

Rinne P, Tikka S, Mäkelä S, Streng T, Savontaus E

Peptides11 Sept 2012Cited by 10 (Europe PMC)

PMID22982611 (opens in a new tab)DOI10.1016/j.peptides.2012.09.004 (opens in a new tab)PepBankPUB-22982611
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In conscious mice, MT-II increased blood pressure in a dose-dependent manner; the pressor effect was less prominent than the tachycardic effect.

    In plain wordsIn conscious mice, melanotan II raised blood pressure, more with higher doses.

    Peptide
    Melanotan II
    Outcome
    IncreaseBlood pressure in conscious mice
    Study

    mousen: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · peripheral routesAs given in this study (mouse).

    Source sentences

    Summary
    In conscious mice, NDP-α-MSH and MT-II increased blood pressure and heart rate in a dose-dependent manner, but the tachycardic effect was more prominent than the pressor effect.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In conscious mice, MT-II increased heart rate in a dose-dependent manner; the tachycardic effect was more prominent than the pressor effect.

    In plain wordsIn conscious mice, melanotan II raised heart rate, more with higher doses.

    Peptide
    Melanotan II
    Outcome
    IncreaseHeart rate in conscious mice
    Study

    mousen: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · peripheral routesAs given in this study (mouse).

    Source sentences

    Summary
    In conscious mice, NDP-α-MSH and MT-II increased blood pressure and heart rate in a dose-dependent manner, but the tachycardic effect was more prominent than the pressor effect.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In anesthetized mice, MT-II induced only mild changes in blood pressure and heart rate compared with conscious mice.

    In plain wordsIn anesthetized mice, melanotan II caused only mild changes in blood pressure and heart rate compared with awake mice.

    Peptide
    Melanotan II
    Outcome
    Direction not reportedBlood pressure and heart rate in anesthetized mice
    Study

    mousen: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · peripheral routesAs given in this study (mouse).

    Source sentences

    Summary
    NDP-α-MSH and MT-II induced mild changes in blood pressure and heart rate in anesthetized mice compared to the effects observed in conscious mice, suggesting that anesthesia distorts the hemodynamic actions of α-MSH analogs.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice, pretreatment with the MC3/4 receptor antagonist SHU9119 abolished the hemodynamic effects of MT-II.

    In plain wordsIn mice, a melanocortin receptor blocker removed the blood pressure and heart rate effects of melanotan II.

    Peptide
    Melanotan II
    Outcome
    No significant changeHemodynamic effects with MC3/4 receptor antagonist SHU9119
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · peripheral routesAs given in this study (mouse).

    Source sentences

    Summary
    Pretreatment with the melanocortin (MC) 3/4 receptor antagonist SHU9119 abolished these hemodynamic effects.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, the beta-1 blocker metoprolol prevented the pressor effect of MT-II and partly its tachycardic action.

    In plain wordsIn mice, the beta-1 blocker metoprolol prevented the blood pressure rise from melanotan II and partly its heart rate rise.

    Peptide
    Melanotan II
    Outcome
    DecreasePressor and tachycardic effects with metoprolol
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · peripheral routesAs given in this study (mouse).

    Source sentences

    Summary
    the blockade of β(1)-adrenoceptors with metoprolol prevented the pressor effect and partly the tachycardic action of α-MSH analogs
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, the ganglionic blocker hexamethonium abrogated completely the heart rate difference between vehicle and MT-II treatment.

    In plain wordsIn mice, the nerve-ganglion blocker hexamethonium completely removed the heart rate difference between melanotan II and vehicle.

    Peptide
    Melanotan II
    Outcome
    No significant changeHeart rate difference with ganglionic blocker hexamethonium
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · peripheral routesAs given in this study (mouse).

    Source sentences

    Summary
    while the ganglionic blocker hexamethonium abrogated completely the difference in heart rate between vehicle and α-MSH treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.